



## **TO THE NATIONAL SECURITIES MARKET COMMISSION**

Madrid, 29 April, 2021

### **PRICE-SENSITIVE INFORMATION**

Complying with the information duties set out in article 226 of the Revised Text of the Securities Market Act, Laboratorios Farmacéuticos ROVI, S.A. (ROVI) issues and publishes the press release attached hereto concerning the expansion of the collaboration that currently exists between ROVI and Moderna for the manufacture of Moderna's COVID-19 vaccine outside the United States. ROVI will increase its fill-finish capacity. The press release will be distributed today and may be accessed through the Company's website.

Juan López-Belmonte Encina  
Chief Executive Officer and General Manager  
Laboratorios Farmacéuticos ROVI, S.A.



## **ROVI increases its fill-finish capacity for the COVID-19 Vaccine Moderna**

- **Investment in two new production lines at ROVI's San Sebastián de los Reyes (Madrid) facility.**
- **These lines will more than double the number of vials of the Moderna vaccine for which there is fill-finish capacity at this facility.**

**Madrid, Spain – 29 April, 2021** – Laboratorios Farmacéuticos Rovi, S.A. (BME: ROVI), a pan-European pharmaceutical company specializing and engaging in the research, development, contract manufacturing and marketing of small molecules and biological specialties, today announced that it will strengthen its collaboration in the fill-finish of the COVID-19 Vaccine Moderna by increasing its fill-finish capacity. To this end, further industrial investments will be made in the ROVI Group's facility in Madrid (Spain).

These investments consist of the installation of two new production lines and equipment for compounding, filling, automatic visual inspection, labelling and packaging that will provide additional fill-finish capacity for the COVID-19 Vaccine Moderna, intended to supply markets outside the United States. These lines, located at ROVI's facility in San Sebastián de los Reyes (Madrid), will come into operation in the fourth quarter of 2021 and be fully operational in the first half of 2022 and will more than double the number of vials for which there is fill-finish capacity at this facility.

Juan López-Belmonte Encina, ROVI's Chief Executive Officer, said, "*We are delighted at our collaboration with Moderna, whose vaccine against COVID-19 is well positioned in the race to try to solve this health crisis. The expansion of our fill and finish capacity will allow us to increase our contribution to solving this pandemic that is affecting everyone. We are confident that our proven experience and capacities as a contract manufacturer of injectables with high technological value will enable us to provide*

*broader support to Moderna in their large-scale distribution. We expect this increased collaboration with Moderna to help us become their long-term manufacturing partner. I would also like to thank the Ministry of Health and the Spanish Medicines Agency for making themselves available to us and providing their support during this entire process. This has been of vital importance”.*

## **About ROVI**

ROVI is a pan-European pharmaceutical company specializing and engaging in the research, development, contract manufacturing and marketing of small molecules and biological specialties. The company, in continual international expansion, has subsidiaries in Portugal, Germany, the United Kingdom, Italy, France and Poland and has a diversified marketing portfolio of more than 40 products, among which its flagship product, Bemiparin, already marketed in 58 countries all over the world, should be highlighted. Likewise, in 2017, ROVI commenced the marketing of its enoxaparin biosimilar, developed in-house, in Europe. ROVI continues to develop the ISM® Platform technology, a leading-edge line of research in the field of prolonged drug release with proven advantages. For more information, please visit [www.rovi.es](http://www.rovi.es).

## **ROVI’s Forward-looking statements**

This news release contains forward-looking statements. Such forward looking statements involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial situation, performance, or achievements of ROVI or the industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward looking statements. These risks, uncertainties, and other factors include, among others: the fact that no commercial product utilising mRNA technology has been approved for use before; the fact that the manufacturing infrastructure required to manufacture mRNA-1273 is still being developed and implemented; potential adverse impacts due to the global COVID-19 pandemic, such as delays in regulatory review, manufacturing and supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy. The statements in this press release represent ROVI's expectations and beliefs as of the date of this press release. ROVI anticipates that subsequent events and developments may cause these expectations and beliefs to change.

However, while ROVI may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing ROVI's expectations or beliefs as of any date subsequent to the date of this press release.

## **ROVI Contacts**

### **Investors:**

Marta Campos Martínez

+34 607 539 780

[mcampos@rovi.es](mailto:mcampos@rovi.es)

Antonio Marquina Ospina

+34 674 315 715

[amarquina@rovi.es](mailto:amarquina@rovi.es)

### **Media:**

Beatriz García Suárez

+34 662 570 818

[bgarciasuarez@rovi.es](mailto:bgarciasuarez@rovi.es)